BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33067267)

  • 21. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells.
    Larocca LM; Capello D; Rinelli A; Nori S; Antinori A; Gloghini A; Cingolani A; Migliazza A; Saglio G; Cammilleri-Broet S; Raphael M; Carbone A; Gaidano G
    Blood; 1998 Aug; 92(3):1011-9. PubMed ID: 9680371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
    Lionakis MS; Dunleavy K; Roschewski M; Widemann BC; Butman JA; Schmitz R; Yang Y; Cole DE; Melani C; Higham CS; Desai JV; Ceribelli M; Chen L; Thomas CJ; Little RF; Gea-Banacloche J; Bhaumik S; Stetler-Stevenson M; Pittaluga S; Jaffe ES; Heiss J; Lucas N; Steinberg SM; Staudt LM; Wilson WH
    Cancer Cell; 2017 Jun; 31(6):833-843.e5. PubMed ID: 28552327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.
    Yonese I; Takase H; Yoshimori M; Onozawa E; Tsuzura A; Miki T; Mochizuki M; Miura O; Arai A
    Eur J Haematol; 2019 Feb; 102(2):191-196. PubMed ID: 30390359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of Pin1 as a Key Molecule for EMT Induction by Activation of STAT3 and NF-κB in Human Gallbladder Cancer.
    Nakada S; Kuboki S; Nojima H; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Miyazaki M; Ohtsuka M
    Ann Surg Oncol; 2019 Mar; 26(3):907-917. PubMed ID: 30610554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus.
    Sharma MC; Gupta RK; Kaushal S; Suri V; Sarkar C; Singh M; Kale SS; Sahoo RK; Kumar L; Raina V
    Indian J Med Res; 2016 May; 143(5):605-15. PubMed ID: 27488004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
    Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
    Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation.
    Song YJ; Jen KY; Soni V; Kieff E; Cahir-McFarland E
    Proc Natl Acad Sci U S A; 2006 Feb; 103(8):2689-94. PubMed ID: 16477006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS).
    Nagano M; Ayaki T; Koita N; Kitano T; Nishikori M; Goda N; Minamiguchi S; Ikeda A; Takaori-Kondo A; Takahashi R
    Intern Med; 2019; 58(6):849-854. PubMed ID: 30880301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.
    Gebauer N; Gebauer J; Hardel TT; Bernard V; Biersack H; Lehnert H; Rades D; Feller AC; Thorns C
    Leuk Lymphoma; 2015 Apr; 56(4):1100-6. PubMed ID: 25030036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.
    Kaulen LD; Denisova E; Hinz F; Hai L; Friedel D; Henegariu O; Hoffmann DC; Ito J; Kourtesakis A; Lehnert P; Doubrovinskaia S; Karschnia P; von Baumgarten L; Kessler T; Baehring JM; Brors B; Sahm F; Wick W
    Acta Neuropathol; 2023 Sep; 146(3):499-514. PubMed ID: 37495858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).
    Liu Y; Yao Q; Zhang F
    Int J Oncol; 2021 Mar; 58(3):371-387. PubMed ID: 33650642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging insights into origin and pathobiology of primary central nervous system lymphoma.
    You H; Wei L; Kaminska B
    Cancer Lett; 2021 Jul; 509():121-129. PubMed ID: 33766752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
    Roychowdhury S; Peng R; Baiocchi RA; Bhatt D; Vourganti S; Grecula J; Gupta N; Eisenbeis CF; Nuovo GJ; Yang W; Schmalbrock P; Ferketich A; Moeschberger M; Porcu P; Barth RF; Caligiuri MA
    Cancer Res; 2003 Mar; 63(5):965-71. PubMed ID: 12615710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time?
    Utsuki S; Oka H; Miyajima Y; Kijima C; Yasui Y; Fujii K
    Brain Tumor Pathol; 2011 Apr; 28(2):145-9. PubMed ID: 21327439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus as a possible etiologic agent in primary central nervous system lymphoma in immunocompetent individuals.
    Tandon A; Challa S; Shanmugam M; Gopalan S; Paul RT; Digumarthi R
    Neurol India; 2009; 57(1):36-40. PubMed ID: 19305074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
    Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
    Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
    Tateishi K; Miyake Y; Nakamura T; Yamamoto T
    Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
    Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
    Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
    Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
    World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.